Journal ArticleDOI
Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's Disease psychosis (Acp-103-020)
Jeffrey L. Cummings,Stuart Isaacson,Roger Mills,Hilde Williams,Kathy Chi-Burris,Rohit Dhall,Clive Ballard +6 more
Reads0
Chats0
About:
This article is published in Journal of the Neurological Sciences.The article was published on 2013-10-15. It has received 13 citations till now. The article focuses on the topics: Pimavanserin & Tolerability.read more
Citations
More filters
Journal ArticleDOI
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
TL;DR: The evidence for both pharmacological and non-pharmacological treatments for cognitive impairment in AD and PD patients are reviewed and treatment options for other concomitant neuropsychiatric and behavioural symptoms, as well as novel treatment strategies will be discussed.
Journal ArticleDOI
Treatment of Psychosis and Dementia in Parkinson’s Disease
TL;DR: For treating PD psychosis, a first step would be eliminating confounding variables, such as delirium, infections, or toxic-metabolic imbalances, followed by simplifying parkinsonian medications as tolerated, if additional treatment is warranted after such interventions.
Journal ArticleDOI
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs
Herbert Y. Meltzer,Bryan L. Roth +1 more
TL;DR: Two recent 5-HT receptor subtype-selective drugs, lorcaserin and pimavanserin, are discussed, which target the 5HT2C and5HT2A receptors and provide new treatments for obesity and Parkinson's disease psychosis, respectively.
Journal ArticleDOI
The serotonergic system in motor and non-motor manifestations of Parkinson’s disease
Philippe Huot,Susan H. Fox +1 more
TL;DR: Critically reviews studies assessing the SERT, as well as 5-HT1A and 5- HT2A receptors in idiopathic PD and animal models of PD, and discusses unmet challenges to effectively treat manifestations of PD using SERT antagonists, 5-ht1A agonists and5-HT2A antagonists.
Journal ArticleDOI
Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.
Barbara S. Connolly,Susan H. Fox +1 more
TL;DR: Management of neuropsychiatric problems in Parkinson's disease primarily uses therapies developed for general psychiatry and cognitive neurology, rather than specifically for PD, however, significant adverse effects, such as worsening of the motor symptoms of PD, can limit use of some drug therapies.